The South San Francisco biotech startup, Denali Therapeutics, that had raised $217 million last year to fight Alzheimer’s, Parkinson’s and ALS, and an additional $130 million from investors in a private placement led by Baillie Gifford, a UK-based mutual fund, has finally spoken about its plans to use the fund. The company is based to discover genes that have been implicated in the diseases mentioned. This project is the one that Denali’s CEO and co-founder, Ryan Watts was working on while at Genentech. The project is related to the LRRK2 gene, which is implicated in Parkinson’s disease. Many companies were working to develop drugs for it, when it was then discovered that those drugs seemed to cause lung problems in animals. Watts is of the opinion that the dosing needs to be adjusted, where the drug would block LRRK2 without causing the lung issues. Apart from this drug compound, Denali is working on others as well. On August 22, 2016, Denali filed an application in Europe to start a clinical trial in healthy volunteers for testing a new drug which is aimed at Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is also working on drugs focused on the APOE genes. These genes are involved in the cholesterol processing in the human body and, are seen to be a key risk factor for Alzheimer’s. Denali also has a research collaboration with F-Star, a UK-based company, to deliver drugs across the blood-brain barrier that keeps medicines from getting into brain tissue.
DelveInsight Blog
Related Article
Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease; GSK Announces Positive Headline Results from EAGLE-1 Phase III Trial; Dupixent sBLA Accepted for FDA Priority Review; Biogen’s QALSODY Received Positive Opinion from CHMP; FDA Granted Orphan Drug Designation to Immune-Onc’s IO-202; Artiva Biotherapeutics’s AlloNK® in Lupus Nephritis
Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis Boehringer Ingelheim has reported that in a Phase II trial, a significant proportion of adults treated with survodutide (BI 456906), up to 83.0%, showed a notable enhancement in metabol...
Find More
FDA Grants Priority Review to BMS’ Luspatercept; Teva and MedinCell’s Risperidone FDA Approval; Biogens’s QALSODY FDA Accelerated Approval; FDA IND Authorization to Kiromic’s Deltacel; Atsena’s ATSN-201 FDA IND Clearance
FDA Grants Priority Review to Luspatercept for First-line Treatment of Anemia in Lower-risk MDS The FDA has granted priority review to a supplemental biologics license application (sBLA) seeking to expand the current indication of luspatercept-aamt (Reblozyl) to include treatment of anemia in patients with very ...
Find More
HUTCHMED’s NDA Submission to FDA for Fruquintinib; Cytokinetics to Discontinue ALS Drug Candidate Following Phase III Trial Failure; Enfortumab Vedotin + Pembrolizumab Approved for Urothelial Carcinoma; Nanoscope Gene Therapy Clears Phase II Retinitis Pigmentosa Trial; FDA Clearance to Cabaletta Bio’s IND Application for CABA-201 for SLE Treatment; European Orphan Drug Designation to Gene Therapy Candidate DB-OTO
HUTCHMED Completes Rolling Submission of NDA to FDA for Fruquintinib HUTCHMED (China) Limited announced the completion of the rolling submission of a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1,...
Find MoreEditor's Pick
Newsletter/Whitepaper
-Agonist.png "Toll-like Receptors Agonist")
Recent Article
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.